<DOC>
	<DOCNO>NCT01742221</DOCNO>
	<brief_summary>This trial design evaluate safety , pharmacokinetics , pharmacodynamics HemaMax healthy male female volunteer .</brief_summary>
	<brief_title>Safety Tolerability HemaMaxâ„¢ ( rHuIL-12 ) Radiation Countermeasure</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Radiation Syndrome</mesh_term>
	<mesh_term>Radiation Injuries</mesh_term>
	<criteria>Male Female subject , sign informed consent form must meet follow criterion 1 . 18 45 year age 2 . Body mass index ( BMI ) &gt; 19 &lt; 0 kg/m2 3 . Normal ECG , vital sign laboratory test result 4 . Use effective birth control method abstinence sex 5 . Negative pregnancy test drug screen Subjects follow characteristic consider ineligible : 1 . History clinically significant renal , hepatic pulmonary , cardiovascular , cerebrovascular , gastrointestinal , metabolic , hematological , endocrine , urological , immunological , neurologic psychiatric disorder connective tissue disease 2 . Positive human immunodeficiency virus ( HIV ) , Hepatitis B , surface antigen ( HBsAg ) Hepatitis C antibody , tuberculosis ( TB ) 3 . Current drug alcohol addiction 4 . History clinically significant allergy kind 5 . Prior use IL12 HemaMax 6 . Use approve investigational biologic agent vaccination kind last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Safety Tolerability , Cytokines , Acute Radiation Syndrome , Hematopoietic Syndrome , Radiation Countermeasure</keyword>
</DOC>